India becoming part of global drug development operation of BMS: Samit Hirawat
The Hindu
Samit Hirawat of Bristol Myers Squibb discusses drug development, clinical trials, and technology in exclusive interview with The Hindu.
As the executive vice president, chief medical officer and head of development at Bristol Myers Squibb, Samit Hirawat oversees early-stage and late-stage product development across therapeutic areas for the biopharmaceutical major. In an exclusive chat with The Hindu, on a recent visit to Hyderabad, he discussed India’s growing significance as a site for clinical trials, innovations in drug development, and how technology is poised to help bring new products to market faster.
Sensex plunges to three-month low as Nifty closes below 24,000 on heavy selling; global factors weigh on market.
Government invites applications for RBI Deputy Governor
Book the 4th generation Dzire from Maruti Suzuki with an initial payment of ₹11,000 at any ARENA showroom.
NTPC and ONGC form 50:50 JVC for renewable energy ventures, including solar, wind, energy storage, and more.
HCLTech announced an AI/Cloud Native Lab in Singapore that will be developed in partnership with the Singapore government.
Rupee trading in narrow range due to strong dollar, rising oil prices, RBI intervention, IPOs, and equity market decline.
India's private sector manufacturing rebounds in October, showing growth in new orders and international sales, boosting business confidence.
Foreign selling drives Indian markets down; Sensex drops 665.27 points, Nifty tanks 229.4 points in early trade.
Quarterly performance of major cement producers, challenges faced, price trends, and expectations for the industry's future growth.
October saw record ₹94,000 crore outflow from Indian stock market due to high valuations, shifting focus to Chinese equities.
Leading FMCG companies face margin decline due to high input costs, food inflation, and slowing urban consumption.